

IDNA

iShares
by BlackRock

Megatrends in focus: Demographics and social change

iShares megatrend ETFs seek to capture the long-term, transformative forces changing societies, driving innovation and redefining business models

Demographics and social change is one such megatrend, with people living longer and healthier lives due to medical breakthroughs.

Accessing companies at the forefront of medical revolutions

The **iShares Genomics Immunology and Healthcare ETF (IDNA)** provides exposure to two growing areas of medical innovation - genomics and immunology - using NYSE FactSet's proprietary data to identify companies with the potential to transform the way we fight disease, including:

IDNA

iShares Genomics Immunology and Healthcare ETF
Expense ratio: 0.47%

INDEX

NYSE FactSet Global Genomics and Immuno Biopharma Index

HOLDINGS

48

INCEPTION DATE

6/11/2019

Source: BlackRock, as of 9/30/2021. Holdings are subject to change.

Genomics - Using an individual's DNA to tailor medical treatment

Bioanalytic Consumables

Genetic Molecular Diagnostic Test Kits

Viral Biopharmaceuticals

Immunology - Using the body's immune system to fight disease

Immunoassays Clinical Diagnostics Devices

Hematological Oncology Biopharmaceuticals

Infectious Diseases Biopharmaceuticals

99.97%

decrease in the cost of mapping an individual's genome from \$1m to \$300 since 2007.¹

\$36B

The market for gene therapies is expected to grow 34% annually, to \$36 billion, by 2027.²

12%

out-performance vs the S&P 1200Healthcare Index. Over the 1-year, IDNA is up 30% compared to the S&P 1500 Healthcare Index which is up 18%.³

Stock examples



Regeneron Pharmaceuticals, Inc. (REGN) utilizes technology that may treat genetically defined diseases at the source by directing changes in DNA.⁴



Moderna, Inc. (MRNA) Develops technologies to instruct a patient's own cells to produce proteins that could prevent, treat, or cure disease.⁵

1 Source: OneZero, "The Price of DNA Sequencing Dropped From \$2.7 Billion to \$300 in Less Than 20 Years" Feb 2020 **2** GlobalNewsWire, "Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR," August 2020. **3** BlackRock, Morningstar 10/1/2020-9/30/2021. Total return shown. All 48 companies in the IDNA exposure are classified as healthcare companies according to the GICS sectors classification system. There is 5.91% exposure overlap between IDNA and the S&P 1200 Healthcare Index. There may be material differences between the fund's index and the index shown including without limitation. S&P's holdings, methodology and performance. Index performance is for illustrative purposes only. **Index performance does not reflect any management fees, transaction costs or expenses. Indexes are unmanaged and one cannot invest directly in an index. Past performance does not guarantee future results. For standardized performance, please see the next page.**

[iShares.com/megatrends](https://www.ishares.com/megatrends)

IDNA characteristics

GICS sub-sector exposure

Biotech




Pharmaceuticals

12%

Life Sciences Tools & Services

6%

Geographic exposure



U.S. style box exposure

	Value	Blend	Growth
Large-cap	8%	21%	9%
Mid-cap	4%	6%	14%
Small-cap	4%	4%	31%

Source: GICS sectors, Morningstar, 9/30/21. Holdings by Country, BlackRock, as of 9/30/21. Holdings are subject to change.

IDNA standardized performance (as of 9/30/21)	1 Year	5 Years	10 Years	Since Inception (6/11/2019)
Fund NAV Total Return	30.57%	--	--	37.82%
Fund Market Price Total Return	30.39%	--	--	37.89%
NYSE FactSet Global Genomics and Immuno Biopharma Index	30.90%	--	--	37.91%

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month end may be obtained by visiting www.iShares.com or www.blackrock.com. Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the fund. Any applicable brokerage commissions will reduce returns. Beginning August 10, 2020, market price returns for BlackRock and iShares ETFs are calculated using the closing price and account for distributions from the fund. Prior to August 10, 2020, market price returns for BlackRock and iShares ETFs were calculated using the midpoint price and accounted for distributions from the fund. The midpoint is the average of the bid/ask prices at 4:00 PM ET (when NAV is normally determined for most ETFs). The returns shown do not represent the returns you would receive if you traded shares at other times. Since shares of a fund may not trade in the secondary market until after the fund's inception, for the period from inception to the first day of secondary market trading in shares of the fund, the NAV of the fund is used as a proxy for the Market Price to calculate market returns.

4 Source: <https://editasmedicine.com/company-overview/> **5** Source: <https://www.modernatx.com> Information on non-iShares Fund securities is provided strictly for illustrative purposes and should not be deemed an offer to sell or a solicitation of an offer to buy shares of any security other than the iShares Funds, that are described in this material. As of 9/30/2021, IDNA had a holding percentage of (4.38%) in REGN and (6.95%) in MRNA. Allocations are subject to change. For a full list of IDNA's holdings, please visit www.ishares.com.

Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Funds' prospectuses or, if available, the summary prospectuses which may be obtained by visiting www.iShares.com or www.blackrock.com. Read the prospectus carefully before investing. Investing involves risk, including possible loss of principal.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/developing markets and in concentrations of single countries. Funds that concentrate investments in specific industries, sectors, markets or asset classes may under-perform or be more volatile than other industries, sectors, markets or asset classes than the general securities market. Companies in the healthcare sector may be affected by government regulations and programs, changes in the cost of medical products and services, changes in the demand for medical products and services among other factors. Healthcare companies are subject to competitive forces that may result in product obsolescence.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

The iShares Funds are not sponsored, endorsed, sold or promoted by ICE Data Services, LLC, or S&P Dow Jones Indices LLC, nor do these companies make any representation regarding the advisability of investing in the Funds. BlackRock is not affiliated with the companies mentioned above.

The iShares Funds are distributed by BlackRock Investments, LLC (together with its affiliates, "BlackRock").

©2021 BlackRock, Inc. All rights reserved. **ISHARES** and **BLACKROCK** are trademarks of BlackRock, Inc., or its subsidiaries in the United States and elsewhere. All other marks are the property of their respective owners. Prepared by BlackRock Investments, LLC, member FINRA. GELM-398483-Q-OCT21-US